VistaGen
Therapeutics is keenly aware that despite decades of well-intentioned awareness
and prevention campaigns, heart disease is still the leading cause of death for
both men and women. The disease kills more than 600,000 Americans each year.
According to the Center for Disease Control, approximately 49 percent of
Americans have at least one of the three risk factors for heart disease – these
being high blood pressure, high LDL cholesterol, and smoking. Despite
researcher insights concluding that an overwhelming majority of heart disease
is the result of poor lifestyle choices, scientists understand the statistics
are dynamic in nature and must be constantly monitored.
VistaGen is a life
sciences company that innovatively leverages its Human Clinical Trials in a
Test Tube™ technology platform to provide clinically relevant predictions of
potential toxicity of promising new drug candidates. Cardiovascular care is one
of VistaGen’s particular areas of focus.
Unexpected safety
concerns are pointed to as the reason why about one-third of all potential new
drug candidates fail in preclinical or clinical development. It is believed
that many lives could have been saved if it were not for promising
cardiovascular drugs being discontinued because of late-stage failure. Using
human heart cells derived from human pluripotent stem cells (hPSCs), VistaGen’s
technology is designed to address potential toxicity of new cardiovascular drug
candidates long before they are ever tested in humans.
CardioSafe 3D™, the
company’s novel three-dimensional (3D) bioassay system, was developed to
identify safer drug rescue variants with reduced heart safety concerns, which
can be missed in animal models or in vitro cell culture testing currently used
by biotechnology and pharmaceutical companies.
VistaGen’s plan is
to combine CardioSafe 3D™ with modern medicinal chemistry to build a pipeline
of safer chemical variants (Drug Rescue Variants™) of once-promising drug
candidates that initially were developed by biotechnology and pharmaceutical
companies, but were abandoned later due to the concerns mentioned earlier.
Other notable work involves AV-101, the company’s lead small molecule drug
candidate. The drug has successfully completed Phase I development in the U.S.
for treatment of neuropathic pain, a serious and chronic condition causing pain
after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects millions of people worldwide. VSTA believes its Phase
1 safety program will enable Phase 2 development of AV-101 for neuropathic
pain, depression, and potentially other neurological conditions. To date,
VistaGen has been awarded over $8.8 million from the NIH for development of
AV-101.
The core goal is to
license or sell Drug Rescue Variants to biotechnology and pharmaceutical
companies for further development and commercialization. VistaGen believes its
strategy has the potential to substantially reduce drug development costs and
produce effective and safer drugs, which would inherently help save human
lives.
For more information
visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment